Medical device developer Reva Medical is looking to list its shares on the Nasdaq market in the United States, with a final decision to be made by mid-2016, notwithstanding the recent disastrous start to Mesoblast's US listing.

Reva, which has the backing of Goldman Sachs along with distributors such as Boston Scientific and Medtronic, is ramping up commercialisation plans for its product, a bioabsorbable stent for inserting in clogged arteries, which are expected to emerge as the next-generation product to take over from metal stents.

Sydney Morning Herald